- Home
- COLL vs IMTX Comparison
COLL vs IMTX Comparison
Compare COLL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | IMTX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | IMTX |
|---|---|---|
| Price | $47.02 | $10.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $47.50 | $19.25 |
| AVG Volume (30 Days) | 550.1K | ★ 648.3K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $757,067,000.00 | $99,445,031.00 |
| Revenue This Year | $26.35 | N/A |
| Revenue Next Year | $3.67 | $24.39 |
| P/E Ratio | $29.21 | ★ N/A |
| Revenue Growth | ★ 26.34 | N/A |
| 52 Week Low | $23.23 | $3.30 |
| 52 Week High | $49.09 | $12.41 |
Technical Indicators
Market Signals| Indicator | COLL | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.88 | 49.21 |
| Support Level | $46.81 | $9.75 |
| Resistance Level | $49.09 | $12.41 |
| Average True Range (ATR) | 1.33 | 0.81 |
| MACD | -0.19 | -0.06 |
| Stochastic Oscillator | 69.59 | 12.22 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.